Laserfiche WebLink
Resolution 21-088 <br /> Page I of 3 <br /> RESOLUTION NO. 21-088 <br /> A RESOLUTION OF THE CITY COUNCIL OF THE CITY OF PORT TOWNSEND, <br /> WASHINGTON, DECLARING THAT THE INVESTIGATION, ARREST,AND <br /> PROSECUTION OF ADULTS ENGAGING IN ENTHEOGEN-RELATED ACTIVITIES <br /> SHOULD BE AMONG THE LOWEST ENFORCEMENT PRIORITIES FOR THE CITY <br /> OF PORT TOWNSEND AND STATING THE COUNCIL'S SUPPORT FOR FULL <br /> DECRIMINALIZATION OF THESE ACTIVITIES <br /> WHEREAS, entheogen is a term that encompasses any living, fresh, dried, or processed <br /> plant or fungal material, including teas or powders, that may contain currently scheduled or analog <br /> psychoactive indolamines, tryptamines, or phenethylamines, including, but not limited to, <br /> psilocybin mushrooms, ayahuasca tea, mescaline, and iboga; and <br /> WHEREAS, depression, severe anxiety, problematic substance use, post-traumatic stress, <br /> end-of-life anxiety, grief, intergenerational trauma, and other physical and mental conditions are <br /> plaguing many communities and have been exacerbated by the impact of COVID-19, and scientific <br /> and clinical studies show the benefits of entheogens in treating these conditions;l and <br /> WHEREAS, clinical trials sanctioned by the U.S. Food and Drug Administration (FDA) <br /> show positive results that potentially demonstrate the safety and efficacy of psilocybin-assisted <br /> therapy;2 and <br /> WHEREAS, the FDA designated psilocybin-assisted therapy as a breakthrough therapy for <br /> treatment-resistant depression in 2018 and major depressive disorder in 2019;3 and <br /> 'Roland R. Griffiths et al.,Psilocybin Produced Substantial and Sustained Decreases in Depression and Anxiety in <br /> Patients with Life-Threatening Cancer: A Randomized Double-Blind Trial,30 JOURNAL OF <br /> PSYCHOPHARMACOLOGY 1181, 1195 (2016); Monnica T. Williams,People of Color in North America Report <br /> Improvements in Racial Trauma and Mental Health Symptoms Following Psychedelic Experiences,28 DRUGS: <br /> EDUCATION,PREVENTION AND POLICY 215 (2020);Robin L. Carhart-Harris et al.,Psilocybin with <br /> Psychological Support for Treatment-Resistant Depression: Six-Month Follow-Up,235 PSYCHOPHARMACOLOGY <br /> 399,400,403-05 (2018);Geoffrey E.Noller, Chris M. Frampton &Berra Yazar-Klosinski,Ibogaine treatment <br /> outcomes for opioid dependence from a twelve-month follow-up observational study,44 AMERICAN JOURNAL OF <br /> DRUG AND ALCOHOL ABUSE 37(2018);Alan K. Davis et al.,Psychedelic Treatment for Trauma-Related <br /> Psychological and Cognitive Impairment Among US Special Operations Forces Veterans,CHRONIC STRESS(Jul. 8, <br /> 2020), 77/2470547020939564;Michael Bogenschutz et al.,Psilocybin- <br /> assisted treatment for alcohol dependence: A proof-of-concept study,29 JOURNAL OF PSYCHOPHARMACOLOGY <br /> 289 (2015);D6bora Gonzdlez et al.,Therapeutic Potential of Ayahuasca in Grief: A Prospective,Observational Study, <br /> 237 PSYCHOPHARMACOLOGY 1171 (2020);Anja Loizaga-Velder and Rolf Verres,Therapeutic effects of ritual <br /> ayahuasca use in the treatment of substance dependence-qualitative results,46 JOURNAL OF PSYCHOACTIVE <br /> DRUGS 63 (2014);Deborah C. Mash et al., Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between <br /> Dependence and Abstinence: Clinical Observations and Treatment Outcomes, 9 FRONTIERS IN PHARMACOLOGY <br /> 529(2018). <br /> 2 Effects of Psilocybin in Major Depressive Disorder, June 1,2021), <br />;Psychopharmacology <br /> of Psilocybin in Cancer Patients, June 1,2021), <br /> https:Hclin 595?term=psilocybin&recrs=e&draw=2&rank=6. <br /> ' Rachel Feltman,The FDA is fast-tracking a second psilocybin drug to treat depression,POPULAR SCIENCE(Nov. <br /> 26,2019), <br />